Fulcrum Shares Plunge Over 50% as FDA Concerns Lead to Scrapping of Key Sickle-Cell Drug

Fulcrum Therapeutics witnessed a significant 52% drop in its share price on Tuesday, following the company’s announcement to halt the development of its experimental sickle-cell disease treatment, pociredir. Concerns raised by the U.S. Food and Drug Administration (FDA) regarding potential cancer risks associated with drugs targeting the PRC2 protein complex played a pivotal role in this decision. This setback underscores broader challenges faced in the sector, as evidenced by Pfizer’s recent withdrawal of its approved therapy Oxbryta over similar safety issues. The reassessment of pociredir’s clinical viability has created uncertainty among investors and analysts alike.

Despite the company’s prior claims that pociredir had a distinct risk profile compared to Tazverik, another drug recently withdrawn for safety concerns, the FDA’s stance suggests a more generalized caution regarding all drugs acting on the PRC2 complex. Analysts from Truist indicated that the FDA is not delineating between sub-units of the complex, heightening systemic cancer risk perceptions. This comprehensive caution has led multiple brokerages to downgrade Fulcrum’s stock and adjust their price targets downward, reflecting the negative sentiment and reevaluation of the company’s future prospects.

The management has pivoted their strategy to consider potential mergers or sales, alongside immediate cost-cutting measures, to navigate the current tumultuous landscape. Notably, they emphasized that while no new safety concerns have emerged in ongoing clinical trials, the regulatory environment surrounding their drug has shifted significantly. Analysts express surprise at the discontinuation due to the promising efficacy data and the pressing unmet medical needs in the sickle-cell disease treatment space, indicating a possible disconnect between clinical results and regulatory interpretations.

Moving forward, investors should remain vigilant regarding further developments on Fulcrum’s strategic alternatives and the regulatory landscape affecting the sickle-cell drug market. The company’s ongoing exploration of partnerships or acquisitions may present new opportunities but comes with inherent risks tied to their regulatory challenges. Continuous monitoring of FDA communications and market reactions will be essential for informed investment decisions in this increasingly volatile sector.

Source: The Economic Times

(Expert Note: This report was prepared by the Wealthova team.)